Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma | Zendy

Sora Kang | Zendy; Changhoon Yoo | Zendy; So Heun Lee | Zendy; Dongwook Oh | Zendy; Tae Jun Song | Zendy; Sang Soo Lee | Zendy; Jae Ho Jeong | Zendy; Do Hyun Park | Zendy; Dong Wan Seo | Zendy; Jinhong Park | Zendy; Dae Wook Hwang | Zendy; Ki Byung Song | Zendy; Jae Hoon Lee | Zendy; Woohyung Lee | Zendy; Bong Jun Kwak | Zendy; Sarang Hong | Zendy; Heung-Moon Chang | Zendy; BaekYeol Ryoo | Zendy; Kyupyo Kim | Zendy; Song Cheol Kim | Zendy

Open Access

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma

Author(s) -

Sora Kang,

Changhoon Yoo,

So Heun Lee,

Dongwook Oh,

Tae Jun Song,

Sang Soo Lee,

Jae Ho Jeong,

Do Hyun Park,

Dong Wan Seo,

Jinhong Park,

Dae Wook Hwang,

Ki Byung Song,

Jae Hoon Lee,

Woohyung Lee,

Bong Jun Kwak,

Sarang Hong,

Heung-Moon Chang,

BaekYeol Ryoo,

Kyupyo Kim,

Song Cheol Kim

Publication year - 2022

Publication title -

therapeutic advances in medical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.272

H-Index - 49

eISSN - 1758-8359

pISSN - 1758-8340

DOI - 10.1177/17588359221097190

Subject(s) - medicine , gemcitabine , capecitabine , hazard ratio , neutropenia , gastroenterology , confidence interval , adjuvant , retrospective cohort study , population , pancreatic cancer , oncology , chemotherapy , surgery , cancer , colorectal cancer , environmental health

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research